Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulodexide for Endothelial Protection in Convalescent COVID-19
NCT05252923Phase 4Terminated
- Sponsor
- Pirogov Russian National Research Medical University
- Start
- Apr 2022
- Primary completion
- Sep 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sulodexide in coronavirus disease 2019 (COVID-19), endothelial dysfunction and inflammation, sponsored by Pirogov Russian National Research Medical University. Primary endpoint: Serum level of soluble Thrombomodulin at 8 weeks. Started Apr 2022; status: terminated.
02
Drugs
sulodexide
03
Conditions
coronavirus disease 2019 (COVID-19)endothelial dysfunctioninflammation
Beyond the preview
Go deeper on NCT05252923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05252923.